Jan 20th 2026 – Remedy Biologics is pleased to announce that Dr Colm Galligan has been appointed to its Board of Directors, effective immediately.
Dr Galligan will contribute strategic oversight into research alliances, and the advancement of Remedy Biologics’ therapeutic platforms. Dr Galligan’s extensive track record, including executive and governance roles at pharmaceutical groups including Novo Nordisk and Merck/ MSD, positions him well to help deepen the company’s collaborative networks and accelerate the translation of our technology into clinical impact.
Dr Galligan previously served the company as Chief Medical Officer, bringing wide experience in establishing and leading collaborative research partnerships. He is a Fellow of the Faculty of Pharmaceutical Medicine (RCP UK) and is Pharmaceutical Medicine specialty registered with the Irish Medical Council and a Chartered Director accredited through the Institute of Directors.
Daniel Crowley, Executive Chairman at Remedy Biologics, said:
“Colm brings decades of experience from Clinical Medicine and the BioPharma sector, and is a highly experienced executive and board member. His insight and leadership will contribute immensely to the company’s journey.”
Colm Galligan commented:
“RemedyBio’s technology allows us to map immune disease interactions at a scale and depth previously unimagined, creating insights which can change how major diseases are treated. I’m excited to contribute to realising the company’s immense potential.”
Dr Galligan’s appointment to the Board is effective as of December 2025
